CLE-100 as an Oral Therapy in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
The clinical trial is a Phase 2, double-blind, randomized, placebo controlled study in Major
Depressive Disorder (MDD) participants currently treated with antidepressant therapy. The
objective of the study is to assess CLE-100 for the treatment of MDD in participants
currently treated with standard antidepressant therapy.